1. Home
  2. SANG vs ALXO Comparison

SANG vs ALXO Comparison

Compare SANG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sangoma Technologies Corporation

SANG

Sangoma Technologies Corporation

HOLD

Current Price

$4.66

Market Cap

157.1M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.24

Market Cap

172.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SANG
ALXO
Founded
1984
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.1M
172.8M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
SANG
ALXO
Price
$4.66
$1.24
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
★ $5.54
$4.60
AVG Volume (30 Days)
127.9K
★ 1.5M
Earning Date
11-13-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.36
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.23
N/A
Revenue Next Year
$0.96
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.40
$0.86
52 Week High
$5.42
$2.66

Technical Indicators

Market Signals
Indicator
SANG
ALXO
Relative Strength Index (RSI) 58.43 47.68
Support Level $4.64 $0.86
Resistance Level $5.02 $1.30
Average True Range (ATR) 0.11 0.15
MACD -0.05 0.04
Stochastic Oscillator 44.74 75.97

Price Performance

Historical Comparison
SANG
ALXO

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic location USA and Other countries. Key revenue is generated from USA.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: